Evidence map›Paper›PMID 32618282›Full record

ArticleThe Lancet. Infectious diseases2020

Testing COVID-19 therapies to prevent progression of mild disease.

Marc Lipsitch, Stanley Perlman, Matthew K Waldor

Abstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Marc LipsitchCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: mlipsitc@hsph.harvard.edu.
Stanley PerlmanDepartment of Microbiology and Immunology and Department of Pediatrics, University of Iowa, Iowa City, IA, USA.
Matthew K WaldorDepartment of Medicine and Department of Microbiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

Vibrio cholerae intestinal colonization and vaccine developmentR01AI042347 · NIAID · TUFTS UNIVERSITY BOSTON · PI WALDOR, MATTHEW K · 1998 to 2025
$7.3M
NIAID NIH HHS R01 AI042347
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusCOVID-19Pneumonia, ViralHumansPandemics

Identifiers

PMID32618282
PMCPMC7202831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.